Physician profile
David W Dewitt
NPI 1215094594
$3,083.49
in general payments reported to CMS, 2019-2025
26 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,050 · 2022: $519 · 2023: $714 · 2024: $527 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.74 | 2021-2023 | |
| Lilly USA, LLC | $398.98 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $281.16 | 2021-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $275.02 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $215.87 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $211.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.31 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $127.47 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.36 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.40 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $97.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.05 | 2022-2025 | |
| Mylan Specialty L.P. | $82.47 | 2022-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $70.49 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.32 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.74 | 2022 | |
| Abbott Laboratories | $38.70 | 2024 | Freestyle Libre 3, Proclaim |
| Pfizer INC. | $34.13 | 2023-2024 | |
| Esperion Therapeutics, INC. | $33.74 | 2023-2025 | Nexletol |
| Ibsa Pharma INC. | $29.75 | 2021 | |
| Genentech USA, INC. | $26.07 | 2021 | |
| Corium, LLC | $25.38 | 2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $22.89 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.03 | 2023 | Quviviq |
| Stryker Corporation | $19.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.